Business Context and Reporting Period
Company: PerkinElmer, Inc. (Note: The filing identifies the registrant as PerkinElmer, Inc., though the request metadata references REVVITY, INC.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 2, 2000
Business Overview: A high-technology company operating in four segments: Life Sciences, Optoelectronics, Instruments, and Fluid Sciences. The company operates in over 100 countries and is a component of the S&P 500 Index.
Key Financial Metrics
| Metric | Three Months Ended July 2, 2000 | Six Months Ended July 2, 2000 |
|---|---|---|
| Sales (Revenue) | $398.7 million | $801.0 million |
| Operating Income | $51.5 million | $87.4 million |
| Net Income | $35.6 million | $51.8 million |
| Diluted EPS (Net Income) | $0.70 | $1.02 |
| Operating Margin | 12.9% | 10.9% |
| Cash and Equivalents | $109.3 million (End of Period) | $109.3 million (End of Period) |
| Short-Term Debt | $335.4 million | $335.4 million |
| Long-Term Debt | $114.9 million | $114.9 million |
| Net Cash from Operations | N/A | $40.7 million |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 31% year-over-year for the quarter and 46% for the six-month period. Organic growth was 12% for the quarter and 11% for the six months, with the remainder driven by acquisitions (notably the Analytical Instruments Division and Vivid Technologies).
- Profitability Surge: Operating income jumped from $1.9 million in Q2 1999 to $51.5 million in Q2 2000. This improvement was driven by strong revenue growth, productivity initiatives, and the absence of a $23 million in-process R&D charge recorded in the prior year related to the AI acquisition.
- Restructuring Credits: The company recognized a $6.3 million restructuring credit in Q2 2000 due to the reevaluation of 1998 plans and lower-than-estimated costs, contrasting with charges in prior periods.
- Segment Performance: The Instruments segment saw the most dramatic turnaround, moving from an operating loss of $25.5 million in Q2 1999 to a profit of $12.7 million in Q2 2000, largely due to the inclusion of the AI acquisition.
Guidance, Outlook, and Risks
- Recent Acquisitions: On July 31, 2000 (subsequent to the reporting period), the company acquired NEN Life Sciences, Inc. for approximately $400 million, financed largely by commercial paper. This expands the Life Sciences portfolio.
- Debt Management: In early August 2000, the company sold $460 million in zero-coupon senior convertible debentures to repay commercial paper borrowings. Interest expense is expected to remain elevated due to increased debt levels from recent acquisitions.
- Restructuring Outlook: The company expects to incur approximately $20 million in cash outlays for restructuring plans for the remainder of fiscal 2000.
- Accounting Changes: The company is evaluating the impact of new revenue recognition guidance (SAB No. 101) and SFAS No. 133 regarding derivatives, though no material effect is currently anticipated.
- Market Risks: Significant exposure to foreign exchange rate fluctuations (Europe and Asia) and interest rate changes. The company utilizes derivative instruments to hedge these risks.
Investor Verification Checklist
- Acquisition Integration: Verify the realization of synergies and cost structure improvements from the Analytical Instruments (AI) and Vivid Technologies acquisitions.
- Debt Servicing: Monitor the impact of the $460 million convertible debenture issuance and the $410 million commercial paper borrowing on future interest expenses and liquidity.
- Restructuring Execution: Track the actual cash outlays against the projected $20 million remaining for restructuring plans to ensure no unexpected liabilities arise.
- Revenue Recognition: Review future filings for any restatements or adjustments resulting from the adoption of SAB No. 101 regarding customer acceptance and installation terms.
- Discontinued Operations: Confirm that the Technical Services segment results remain fully segregated and that no further contingent gains or losses are expected from the sale.